Genomic Health Google Finance

Genomic Health, now Exact Sciences, was a pioneering company in the field of genomic diagnostics, using genomic analysis to personalize cancer treatment decisions. While the ticker symbol "GENE" no longer exists on Google Finance as an independent entity, its history and influence on the healthcare landscape are notable.

Before its acquisition by Exact Sciences in 2019, Genomic Health focused on developing and commercializing genomic-based diagnostic tests for cancer. Their flagship product, the Oncotype DX test, analyzed the expression of specific genes within a tumor sample to predict the likelihood of cancer recurrence and the potential benefit from chemotherapy. This information empowered physicians and patients to make more informed treatment choices, potentially avoiding unnecessary and often debilitating chemotherapy in cases where the risk of recurrence was low or the benefit of chemotherapy was minimal.

The company's business model revolved around providing these diagnostic tests to oncologists and pathologists. The Oncotype DX test was available for breast cancer, colon cancer, and prostate cancer. By providing personalized risk assessments, Genomic Health aimed to reduce healthcare costs, improve patient outcomes, and enhance the overall quality of cancer care.

Genomic Health's financial performance was closely watched by investors. The company's revenue was primarily driven by sales of its Oncotype DX tests. Key metrics included the number of tests ordered, the average selling price per test, and the cost of goods sold. Investors also paid close attention to the company's research and development expenses, as the development of new diagnostic tests was crucial for future growth. Furthermore, reimbursement rates from insurance companies and government healthcare programs played a significant role in the company's financial success.

The acquisition by Exact Sciences marked a significant moment for Genomic Health and the broader genomic diagnostics industry. Exact Sciences, known for its Cologuard non-invasive colon cancer screening test, saw a strategic fit with Genomic Health's expertise in genomic analysis and personalized oncology. The merger brought together two leading companies in the cancer diagnostics space, creating a larger and more diversified entity with a broader portfolio of products.

Following the acquisition, the Genomic Health brand was integrated into Exact Sciences. The Oncotype DX tests remain available and continue to play an important role in personalized cancer treatment. While the "GENE" ticker is no longer active, the legacy of Genomic Health as a pioneer in genomic diagnostics lives on within Exact Sciences. The insights gained from its work have significantly advanced the field of personalized medicine and continue to influence cancer treatment decisions today.

For those interested in the financial performance and strategy of the combined entity, researching Exact Sciences (EXAS) on Google Finance and other financial platforms would be the appropriate path.